Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02306876 · ClinicalTrials.gov registry record · Phase 1

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males

A Phase 1 study, sponsored by Pfizer.

Terminated
Registry status
Phase 1
Development phase
77
Enrollment target

NCT02306876: Clinical Trial Phase 1 study, sponsored by Pfizer.

NCT02306876 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 77 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (28% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02306876, a Phase 1 study, was terminated before completion, sponsored by Pfizer.

TERMINATED
Registry status
Phase 1
Development phase
77 participants
Enrollment target

Study Summary

This study is designed to investigate the safety, tolerability pharmacokinetics and pharmacodynamic effects of PF-06412562 following multiple dose administration as MR tablets in healthy adult males.

Primary Outcome

Columbia Suicide Severity Rating Scale

Interventions

  • OTHER Placebo
  • DRUG PF-06412562 3mg BID
  • DRUG PF-06412562 15mg BID

Trial Details

FieldValue
Enrollment Target 77 participants
Start Date 2015-01-19
Est. Completion 2016-06-14
Phase Phase 1
Pfizer

1,845 total trials

Why NCT02306876 stopped before completion

NCT02306876 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (28% higher).

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT02306876 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02306876 about?

NCT02306876 is a clinical study titled "A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males". This study is designed to investigate the safety, tolerability pharmacokinetics and pharmacodynamic effects of PF-06412562 following multiple dose administration as MR tablets in healthy adult males.

What is the current status of trial NCT02306876?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2015-01-19. Estimated completion is 2016-06-14.

What interventions are being tested in trial NCT02306876?

The interventions under investigation include: Placebo (OTHER), PF-06412562 3mg BID (DRUG), PF-06412562 15mg BID (DRUG).

Who is sponsoring clinical trial NCT02306876?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02306876's enrollment target sits among peer trials

77 703rd of 2000 higher than 1,296 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02127398 · 77 participants · Phase 2

    Stool Transplants to Treat Refractory Clostridium Difficile Colitis

  • NCT04159103 · 77 participants · Phase 1

    Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia

  • NCT04683003 · 77 participants · Phase 3

    A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

  • NCT05004116 · 77 participants · Phase 1

    A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02306876, the US trial registry maintained by the National Library of Medicine. NCT02306876 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.